Prostate cancer worldwide: updated epidemiology, disparities, and screening implications
Abstract
Abstract Background Prostate cancer epidemiology is evolving because of three simultaneous factors: a rising global burden, population aging, and renewed debate about how early detection can reduce advanced disease without returning to non-risk-adapted PSA testing. This Review provides an updated overview of prostate cancer incidence, mortality, prevalence, risk factors, disparities, and screening implications. Methods We synthesized recent systematic reviews, meta-analyses, randomized screening trials, and population-based registry data, supplemented by landmark historical studies. Results Current trends cannot be interpreted without accounting for screening policy, diagnostic intensity, access to MRI and biomarkers, inherited susceptibility, and health-system capacity. Age, family history, ancestry, and germline risk remain the strongest determinants. Most modifiable exposures are weaker and inconsistent, and are better framed within cardiometabolic health and survivorship care. Organized, risk-adapted pathways integrating PSA, MRI, biomarkers, and baseline risk may better preserve early-detection benefits while reducing overdiagnosis and inequity. Conclusions Progress will depend on preventing metastatic disease, minimizing overtreatment, and implementing modern diagnostics equitably.
// Source
Authors: Rui Miguel Marques Bernardino, David‐Dan Nguyen, Sigrid Carlsson, Giorgio Gandaglia, Zeyad R. Schwen, Nicolas A. Soputro, Mohamad Watfa, Abdulrahman Muataz Al-Bayati, Mohammad El Hussein, Rebecca Campbell, Karim Daher, Salim Younis, Jane Nguyen, Christopher J. Weight, Carlo La Vecchia, Alexandre R. Zlotta, Cosimo De Nunzio, Firas Abdollah, Jonathan Evan Shoag, Spyridon P. Basourakos, Frederico Ferronha, Andrea Cosenza, Christopher Wallis, Quoc‐Dien Trinh, Neil E. Fleshner, Jihad H Kaouk, Riccardo Autorino B
Institutions: University of Pittsburgh, University of Toronto, Case Western Reserve University, German Cancer Research Center, Lund University, University of Milan, Administração Regional de Saúde de Lisboa e Vale do Tejo, Azienda Ospedaliera Sant'Andrea, Cleveland Clinic, Henry Ford Hospital, Henry Ford Health, University Hospitals Cleveland Medical Center, IRCCS Ospedale San Raffaele, Glickman Urological Institute